• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用HPLC/DAD/MS/MS技术并结合绿色度分析对etrasimod进行稳定性指示方法的开发与验证。

Development and validation of stability-indicating method of etrasimod by HPLC/DAD/MS/MS technique with greenness profiling.

作者信息

Kovačić Jelena, Amidžić Klarić Daniela, Turk Nikša, Krznarić Željko, Mornar Ana

机构信息

Department of Pharmaceutical Analysis, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.

Department of Gastroenterology, University Hospital Centre, Zagreb, Croatia.

出版信息

Heliyon. 2024 Jul 4;10(13):e34066. doi: 10.1016/j.heliyon.2024.e34066. eCollection 2024 Jul 15.

DOI:10.1016/j.heliyon.2024.e34066
PMID:39071639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11283000/
Abstract

Etrasimod, a novel selective sphingosine-1-phosphate receptor modulator, was recently approved by the U.S. Food and Drug Administration and the European Medicinal Agency for the treatment of moderately to severely active ulcerative colitis in adults. In this research, the forced degradation study as an integral part of drug product and packaging development, which generates data on degradation mechanisms, is published. The development and validation of the stability-indicating method using a superior high-performance liquid chromatography technique coupled with a diode array detector and tandem mass spectrometer was performed to support the forced degradation study and monitor the formation of degradation products. Etrasimod demonstrated good stability under elevated temperature and basic stress conditions, while acidic hydrolysis, oxidative, and photolytic degradation produced eight degradation products. The knowledge of degradation products will be useful in the long-term stability study for establishing the acceptance criteria of etrasimod as a drug substance and dosage form during quality control and stability assessment. The eco-friendliness of the developed forced degradation procedure was evaluated using various greenness appraisal tools. The green metric tools showed that the forced degradation procedure obeys eco-friendly conditions.

摘要

艾曲莫德是一种新型的选择性1-磷酸鞘氨醇受体调节剂,最近已获美国食品药品监督管理局和欧洲药品管理局批准,用于治疗成人中度至重度活动性溃疡性结肠炎。在本研究中,作为药品和包装开发不可或缺的一部分的强制降解研究已发表,该研究生成了降解机制的数据。采用一种结合二极管阵列检测器和串联质谱仪的高效液相色谱技术进行稳定性指示方法的开发和验证,以支持强制降解研究并监测降解产物的形成。艾曲莫德在高温和碱性应激条件下表现出良好的稳定性,而酸性水解、氧化和光解降解产生了8种降解产物。降解产物的相关知识将有助于长期稳定性研究,以便在质量控制和稳定性评估过程中确定艾曲莫德作为原料药和剂型的验收标准。使用各种绿色评估工具对所开发的强制降解程序的生态友好性进行了评估。绿色指标工具表明,强制降解程序符合生态友好条件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/deb7f6d7536a/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/5b2d37c794fe/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/360629265822/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/5b715c3f7660/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/cd247dc98eb3/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/9580f04f9cad/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/cb734e8f85c5/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/deb7f6d7536a/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/5b2d37c794fe/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/360629265822/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/5b715c3f7660/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/cd247dc98eb3/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/9580f04f9cad/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/cb734e8f85c5/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/350a/11283000/deb7f6d7536a/gr7.jpg

相似文献

1
Development and validation of stability-indicating method of etrasimod by HPLC/DAD/MS/MS technique with greenness profiling.采用HPLC/DAD/MS/MS技术并结合绿色度分析对etrasimod进行稳定性指示方法的开发与验证。
Heliyon. 2024 Jul 4;10(13):e34066. doi: 10.1016/j.heliyon.2024.e34066. eCollection 2024 Jul 15.
2
Forced degradation and impurity profiling: recent trends in analytical perspectives.强制降解和杂质剖析:分析视角的最新趋势。
J Pharm Biomed Anal. 2013 Dec;86:11-35. doi: 10.1016/j.jpba.2013.07.013. Epub 2013 Jul 31.
3
LC/Q-TOF-MS-based structural characterization of enasidenib degradation products and establishment of a stability-indicating assay method: Insights into chemical stability.基于 LC/Q-TOF-MS 的依尼西尼降解产物结构特征分析及专属性含量测定方法的建立:对化学稳定性的深入了解。
Rapid Commun Mass Spectrom. 2024 Mar 15;38(5):e9696. doi: 10.1002/rcm.9696.
4
Development and greenness assessment of a stability-indicating HPLC-DAD method for simultaneous determination of allopurinol and benzbromarone.建立并评价一种高效液相色谱-二极管阵列检测法,用于同时测定别嘌醇和苯溴马隆的含量及其稳定性。
Drug Dev Ind Pharm. 2021 Jun;47(6):887-896. doi: 10.1080/03639045.2021.1916522. Epub 2021 Jun 25.
5
Etrasimod: First Approval.依特司莫单抗:首次获批
Drugs. 2024 Feb;84(2):247-254. doi: 10.1007/s40265-024-01997-7.
6
Development of a stability-indicating assay method by HPLC-DAD and MS characterization of forced degradation products of ravuconazole.建立 HPLC-DAD 法测定稳定性并采用 MS 对拉夫康唑的强制降解产物进行结构确证。
J Chromatogr Sci. 2022 Feb 16;60(2):157-163. doi: 10.1093/chromsci/bmab064.
7
Stability-indicating assay method for determination of actarit, its process related impurities and degradation products: Insight into stability profile and degradation pathways.用于测定阿克他利及其工艺相关杂质和降解产物的稳定性指示测定方法:对稳定性概况和降解途径的深入了解。
J Pharm Anal. 2014 Dec;4(6):374-383. doi: 10.1016/j.jpha.2014.01.002. Epub 2014 Jan 25.
8
Identification and determination of related substances of ceftaroline fosamil in medicinal product by high performance liquid chromatography with diode array detection and tandem mass spectrometry.采用高效液相色谱-二极管阵列检测和串联质谱法对药品中头孢洛林酯的有关物质进行鉴别和测定。
J Pharm Biomed Anal. 2017 Oct 25;145:651-660. doi: 10.1016/j.jpba.2017.07.060. Epub 2017 Aug 1.
9
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.艾曲莫德治疗溃疡性结肠炎的长期安全性和有效性:来自OASIS研究开放标签扩展的结果。
J Crohns Colitis. 2021 Jun 22;15(6):950-959. doi: 10.1093/ecco-jcc/jjab016.
10
Liquid chromatography/electrospray ionization tandem mass spectrometry study of repaglinide and its forced degradation products.瑞格列奈及其强制降解产物的液相色谱/电喷雾电离串联质谱研究
Rapid Commun Mass Spectrom. 2018 Aug 15;32(15):1181-1190. doi: 10.1002/rcm.8151.

引用本文的文献

1
Characterization of Pharmaceutical Transformation Products by High-Field Asymmetric Waveform Ion Mobility and Infrared Ion Spectroscopy Coupled to Mass Spectrometry.通过高场非对称波形离子迁移率和红外离子光谱与质谱联用对药物转化产物进行表征
J Am Soc Mass Spectrom. 2025 Jun 4;36(6):1277-1285. doi: 10.1021/jasms.5c00039. Epub 2025 May 12.
2
The Stability-Indicating Ultra High-Performance Liquid Chromatography with Diode Array Detector and Tandem Mass Spectrometry Method Applied for the Forced Degradation Study of Ritlecitinib: An Appraisal of Green and Blue Metrics.采用二极管阵列检测器和串联质谱的稳定性指示超高效液相色谱法用于利特昔替尼的强制降解研究:绿色和蓝色指标评估
Pharmaceuticals (Basel). 2025 Jan 17;18(1):124. doi: 10.3390/ph18010124.

本文引用的文献

1
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus.炎症性肠病患者应用小分子药物的心血管事件预防与管理:国际德尔菲共识。
Dig Liver Dis. 2024 Aug;56(8):1270-1280. doi: 10.1016/j.dld.2024.03.010. Epub 2024 Apr 6.
2
2023 FDA approvals in gastroenterology and hepatology.2023年美国食品药品监督管理局在胃肠病学和肝病学领域的批准情况。
Nat Rev Gastroenterol Hepatol. 2024 Apr;21(4):219. doi: 10.1038/s41575-024-00916-1.
3
Etrasimod: First Approval.
依特司莫单抗:首次获批
Drugs. 2024 Feb;84(2):247-254. doi: 10.1007/s40265-024-01997-7.
4
Size exclusion chromatography as green support for forced degradation study of adalimumab.体积排阻色谱法作为阿达木单抗强制降解研究的绿色支持。
Acta Pharm. 2023 Dec 26;73(4):709-721. doi: 10.2478/acph-2023-0044. Print 2023 Dec 1.
5
The quality of drugs and drug products - Always guaranteed?药品和药物产品的质量 - 始终有保证吗?
J Pharm Biomed Anal. 2024 Feb 15;239:115880. doi: 10.1016/j.jpba.2023.115880. Epub 2023 Dec 10.
6
Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.S1P1受体调节剂药物治疗中重度溃疡性结肠炎患者的疗效与安全性
J Clin Med. 2023 Jul 30;12(15):5014. doi: 10.3390/jcm12155014.
7
Disposition and Mass Balance of Etrasimod in Healthy Subjects and In Vitro Determination of the Enzymes Responsible for Its Oxidative Metabolism.依特司莫在健康受试者中的处置和物质平衡,以及体外鉴定其氧化代谢的相关酶。
Clin Pharmacol Drug Dev. 2023 Jun;12(6):553-571. doi: 10.1002/cpdd.1255. Epub 2023 May 3.
8
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.埃特拉莫德用于溃疡性结肠炎的诱导和维持治疗(ELEVATE):两项随机、双盲、安慰剂对照的3期研究。
Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2.
9
Prognostication in inflammatory bowel disease.炎症性肠病的预后评估
Front Med (Lausanne). 2022 Oct 6;9:1025375. doi: 10.3389/fmed.2022.1025375. eCollection 2022.
10
Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine.鞘氨醇-1-磷酸在炎症性肠病中的调节作用:阻止淋巴细胞进入肠道
Biomedicines. 2022 Jul 19;10(7):1735. doi: 10.3390/biomedicines10071735.